Scimago Lab
powered by Scopus
Formerly the IP & Science
business of Thomson Reuters


eISSN: 1643-3750

Primary sclerosing cholangitis in Ubiquitin treatment - a report of 3 cases

Irena Ciećko-Michalska, Józef Bogdał, Gabriel Turowski

Med Sci Monit 1997; 3(2): CS238-241

ID: 500719

Published: 1997-03-03

Treatment of primary sclerosing cholangitis is a difficult and still not a fuly solved problem . Both monotherapy and combined pharmacological therapy have shown little effect on inhibiting the disease process and preventing complications. In 1994 attempts at applying ubiquitin biotherapy were made by using a thymus extract (TFX-Polfa) which proved to be a ubiquitin preparation, not only active in the immune system but also playing a significant role in regenerative and adjuvant processes. Methods: The study included 3 patients with primary sclerosing cholangitis who were given ubiquitins at a dose of 30 mg weekly for 3 months followed by 20 mg weekly for 6 months or longer. The patients were assessed biochemically and immunologically. Conclusions: Preliminary results of our study show a beneficial effect of ubiquitin biotherapy on the liver.

Keywords: primary sclerosing cholangitis, Ubiquitin, biotherapy